TUMMIDI SANTOSH

Dr. TUMMIDI SANTOSH

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TSTUMMIDI SANTOSH
TUMMIDI SANTOSH
KKKanchan Kothari
Kanchan Kothari
MAMona Agnihotri
Mona Agnihotri
LNLeena Naik
Leena Naik
PSPrashant Sood
Prashant Sood
Background: Fibroepithelial lesions of the breast include fibroadenoma (FA) and phyllodes tumor (PT). Fibroadenomas are benign while phyllodes tumor range from benign, indolent neoplasms to malignant tumors capable of distant metastasis. Our study was to determine the select cytologic features that can accurately distinguish FA from PT. Methods: A retrospective review was performed of patients who had histopathology follow up of FA or PT and on whom a pre-operative fine needle aspiration was performed. Cytologic criteria i.e. epithelial component, stromal component and background cellularity were assessed. Results: 46 FA and 24 PT were specimens were reviewed. Median age and tumor size for FA and PT were 23.0 and 39.0 years, and 2.0 and 5.0 cm, respectively. Univariate analysis and regression models based on generalized estimating equations revealed that large opened out, folded epithelial sheets, frayed and irregular stromal fragment contours, spindle stromal cell nuclei, spindle cell nuclei in the background and background cell atypia are significant cytological predictors of PT. The GEE regression model achieved 78.9% diagnostic accuracy (p < 0.001) in identifying PT based on cytological features. Median epithelial: stromal ratio was 3.4 and 2.6 for FA and PT, respectively. Conclusion: Presence of large, opened out, folded epithelial sheets, frayed and irregular stromal contours with spindle nuclei, background spindle cells and atypia can help distinguish PT from FA.

12 September 2019 in Indian Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KKKanchan Kothari
Kanchan Kothari
TSTUMMIDI SANTOSH
TUMMIDI SANTOSH
MAMona Agnihotri
Mona Agnihotri
PSPragati Sathe
Pragati Sathe
LNLeena Naik
Leena Naik

1 January 2020 in Journal of Cytology
Verified
Journal Article
Open access
PDF file
TSTUMMIDI SANTOSH
TUMMIDI SANTOSH
HPHemlata Panwar
Hemlata Panwar
PIPooja Ingle
Pooja Ingle
VSVandita Singh
Vandita Singh
ABAmit Bugalia
Amit Bugalia
NHNighat Hussain
Nighat Hussain
Background: International Academy of Cytology (IAC) has established a process to produce comprehensive and standardized approach to fine-needle aspiration cytology (FNAC) reporting. They have categorized the breast lesions in C1 to C5. (C1-Insufficient material, C2-Benign, C3- Atypical, C4-Suspicious & C5-Malignant). Aims and Objectives: The aim of study is to classify various breast lesions (C1 to C5) and to grade breast carcinoma on FNAC using Robinson's grading system which is then correlated with modified Bloom–Richardson grading. Materials and Methods: All routine FNAC for breast lump were included in the study during the period from Jan 2016 to Jan 2017. The study was conducted in the Department of pathology and lab medicine of a tertiary care hospital in central India. Results: A total 225 female patients were included in the study, with an age group ranging from 15 - 79 years, with lesions in breast were taken. C1 lesions were found in 3 cases, C2 in 186 cases, C3 in 13 cases, C4 in 4 cases, and C5 in 19 cases. Correlation of cytohistological grading was obtained in 108 cases. Conclusion: Cytological categorization based on IAC structured reporting will enhance the reproducibility of reports among pathologist & clinicians. With the comparison between cytohistological nuclear grading, the cytoprognostic scores will help in evaluating the aggressiveness of tumor, predicts histological grade and prognosis. It could be a useful parameter for selecting neo-adjuvant chemotherapy.

1 April 2022 in The Egyptian Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
ASArundhathi Shankaralingappa
Arundhathi Shankaralingappa
TSTUMMIDI SANTOSH
TUMMIDI SANTOSH
TBThirunavukkarasu Arun Babu
Thirunavukkarasu Arun Babu
Introduction: Platelets are not only involved in hemostasis and coagulation, but play a significant role in innate immunity and inflammatory response. Excess production of cytokines and acute phase reactants affect megakaryopoiesis resulting in the release of immature platelets from the bone marrow altering platelet indices. Aim: To study platelet indices in RT-PCR-proven COVID patients and non-COVID patients. Methods: A case-control study was conducted on 199 COVID-19 patients and 198 normal individuals. Blood samples were analyzed in an automated hematology analyzer. The platelet indices like platelet count, mean platelet volume (MPV), platelet distribution width (PDW), platelet large cell count (PLCC), and platelet large cell ratio (P-LCR) were compared among two groups. Results: Platelet count in COVID-19 patients were significantly low (p<0.01) compared to controls, and a significant number of COVID-19 patients had thrombocytopenia. Plateletcrit (PCT) was also significantly decreased in COVID-19 patients compared to non-COVID individuals. MPV, PDW, and PLCR were significantly (p<0.05) high in COVID-19 patients in comparison to controls, but was not significantly raised in a large number of cases. In contrast, there were no significant differences in platelet large cell count (PLCC) values between COVID-19 cases and non-COVID-19 controls. Conclusion: Platelet indices like platelet count, PCT, MPV, PDW, and P-LCR are significantly altered in COVID-19 infection and thereby can be used as biomarkers in COVID-19. Further research is needed to find if these simple, cost-effective parameters can be used to predict the severity and prognosis in COVID-19 infection.

27 August 2021 in Acta Cytologica
Verified
Journal Article
Closed access
PDF file
NANeha Agrawal
Neha Agrawal
KKKanchan Kothari
Kanchan Kothari
TSTUMMIDI SANTOSH
TUMMIDI SANTOSH
PSPrashant Sood
Prashant Sood
MAMona Agnihotri
Mona Agnihotri
VSVyoma Shah
Vyoma Shah
Introduction: Breast cancer is rapidly emerging as the leading cause of cancer in Indian women. Robust cytopathology and histopathology services are required to tackle this growing burden. The use of rapid on-site evaluation (ROSE) and the International Academy of Cytology (IAC) Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy (FNAB) Cytopathology, which offers structured protocols, are expected to improve breast cytopathology reporting. Methods: We retrieved the cytopathology slides, categorized them by the IAC Yokohama System and histopathology data of all the patients who had been investigated for breast lesions from September 2016 to December 2018, and compared the cytopathology and histopathology. Risk of malignancy (ROM) and performance metrics, like sensitivity, specificity, predictive values, accuracy, and area under the curve were computed. Results: A total of 1,147 FNABs were evaluated, of which 442 (38.5%) underwent ROSE and 624 (54.4%) histopathology. Reported using IAC categories, our cohort recorded 4.9% inadequate, 65.3% benign, 7.8% atypical, 3.3% suspicious for malignancy, and 18.7% malignant lesions. The overall sensitivity and specificity for identifying in situ and malignant lesions were 99.1% and 99.3%, respectively, and were substantially improved by ROSE. ROSE improved the concordance between cytopathology and histopathology from 76.9% to 90.2%, by reducing inadequate (p < 0.001) cases. The ROM increased along a gradient from inadequate to malignant categories, with the gradient being sharpened by ROSE. The false negativity rate was 0.7% and false positivity rate 0%. Conclusion: Incorporating ROSE and the IAC Yokohama System for breast cytopathology reporting improves accurate diagnosis of breast lesions, prevents missed diagnoses, and provides reliable estimates of ROM. These protocols also aid in standardizing a reproducible system for monitoring and auditing of breast pathology services, identify areas that need strengthening, and improve training at pathology centers.

28 June 2022 in Journal of Oral and Maxillofacial Pathology
Verified
Journal Article
Open access
NPNagiredla Puneeta
Nagiredla Puneeta
TSTUMMIDI SANTOSH
TUMMIDI SANTOSH
IMIsha Mishra
Isha Mishra
PGPravin Gaikwad
Pravin Gaikwad
ASAnshuta Sahu
Anshuta Sahu
Background: Oral cancer is the 11thcommon cancer in the world and ranks 6thglobally in deaths. The incidence of oral cancer in India accounts for approximately 30%–40% of all cancers.Aims and Objective: The present study was undertaken to evaluate the expression of Vimentin and E-cadherin in different grades of oral epithelial dysplasias (OEDs) and oral squamous cell carcinoma (OSCC).Materials and Methods: Biopsies/blocks of oral cavity lesions were retrieved from the archives of the department. Normal oral mucosa (5 cases), oral epithelial dysplastic (60 cases) and different grades of OSCC (60 cases) evaluated by hematoxylin and eosin sections. Immunohistochemical analysis was done on the blocks and expression of E-cadherin and Vimentin was recorded.Results: Our study included various grades of OED, OSCC and normal mucosa as control cases. The mean age of OED and OSCC was 49 and 56 years, respectively, with male predominance. Tobacco habit was present in approximately 90% cases, and buccal mucosa was the most commonly involved site in oral cavity with whitish patch and ulceroproliferative lesions being the common clinical presentations respectively. In OED, downregulation and altered localization of e-cadherin (81.6%) and increased expression of vimentin (52.3%) along with their concurrent increase in the stroma represent epithelial mesenchymal transition. In OSCC, reduction in expression (<50%) for e-cadherin (56.6%) with altered localization for e-cadherin was seen in 88.3% of OSCC along with neoexpression of vimentin in the epithelial cells was seen in 68.3% suggestive of mesenchymal phenotypic modification (P= 0.05).Conclusion: It is very crucial to evaluate the invasiveness of dysplasia and tumor with specific molecular biomarker that may help in early prediction of malignancy and also guide in deciding best treatment strategy for established cases of malignancy.